Please login to the form below

Not currently logged in
Email:
Password:

CSCC

This page shows the latest CSCC news and features for those working in and with pharma, biotech and healthcare.

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Sanofi’s PD-1 inhibitor starts EU review for skin cancer

Sanofi’ s PD-1 inhibitor starts EU review for skin cancer. Cemiplimab could be the first PD-1-targeting drug approved for CSCC. ... As of yet, none of the other PD-1/PD-L1-targeting drugs are approved for CSCC.

Latest news

  • Sanofi/Regeneron start first filings for PD-1 drug cemiplimab Sanofi/Regeneron start first filings for PD-1 drug cemiplimab

    CSCC is the second deadliest skin cancer after melanoma, and while quite treatable if caught early it is very serious in the advanced stages. ... Advanced CSCC is responsible for 3, 900 to 8, 800 deaths per year in the US, ”said Regeneron’s clinical

  • Archive listing

    Cemiplimab could be the first PD-1-targeting drug approved for CSCC. .

More from news
Approximately 2 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics